Effect of duration of prior cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) therapy (<= 6 mo or > 6 mo) on alpelisib benefit in patients with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-), PIK3CA-mutated advanced breast cancer (ABC) from BYLieve